CClinicalTrials.gg
Status unknownNCT01657058FI-FORMUpdated Mar 7, 2014

Effects of Mode of Administration of Soluble Fibre Blend on Glycemia, Appetite & Sensory Parameters

A Phase 1/2 interventional study of Soluble viscous fibre blend powder in hydrophobic matrix and Soluble viscous fibre blend in pre hydrated form in Healthy, sponsored by Unity Health Toronto. Status unknown at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-07.

Sponsored by Unity Health Toronto · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2014), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Soluble, viscous fibre has been established as an effective dietary component for lowering postprandial glycemia and promoting satiety. The effectiveness of viscous fibre has been related to its ability to increase the viscosity of the intra-luminal contents of the small intestine. Hence, the proposed mechanism with which soluble fibre affects the glycemic response, dependent on the viscosity development in the gut, would require that soluble fibre be extractable from the food matrix. This, in part, may be dependent on the food matrix that the soluble fibre is incorporated in. While properties of soluble fibre and their physiological effects have been studied extensively, limited data exists on the most effective mode of administration of fibre to optimize benefits. Furthermore, there are no studies to date that have evaluated how different modes of highly viscous soluble fibre would affect the subsequent meal. Hence, we propose a research study to determine whether the form of administration, taking into consideration the carbohydrate availability of a viscous fibre blend supplement, has a significant impact on postprandial and second meal glycemic response and subjective satiety in healthy individuals.

Read the detailed description

Following a 10-12 hr overnight fast, subjects will visit the Risk Factor Modification Centre between 8:00 am and 1:00 pm. Blood pressure and anthropometric measurements, including body weight, height, and % body fat will be taken. An initial finger prick fasting blood sample will be taken and a subjective appetite questionnaire in the form of a 100 mm visual analog scale will be completed. Subsequently, one of the 5 study meals will be administered to the subject to consume over a 10-15 minute duration accompanied by 300ml of water. Subjects will then be asked to complete a palatability questionnaire. Over the following 3 hours capillary blood samples will be taken by finger pricks at 15, 30, 45, 60, 90, 120 and 180 minutes post treatment. Appetite and symptoms questionnaires will be completed at 15, 30, 45, 60, 75, 90, and 120. At 180 min, a second standardized meal will be administered, consisting of 400kcal of pizza and 200ml of water. Further finger pick blood samples will be taken at 15, 30, 45, 60 and 120 min post pizza consumption. Upon completion of the visit, subjects will be given a 24-hour symptoms questionnaire to complete at home as an additional safety measure for a 24-hour period.

02

Conditions studied

  • Healthy

Keywords

  • soluble fiber
  • second meal effect
  • glycemia
  • satiety
  • Individuals
03

In context

Lead sponsor

Unity Health Toronto is the lead sponsor of 434 studies on the registry; 76 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • age 18-65 years
  • normal glycemic response
  • BMI between 18.5 - 25 kg/m2
  • peripheral systolic and diastolic blood pressure \<140 mmHg and \<90 mmHg, respectively.

Exclusion criteria

Exclusion Criteria:

  • Known reported history of liver or kidney disease, diabetes, hypertension, stroke or myocardial infarctions, thyroid disease, Celiac disease/gastrointestinal disease, or AIDS
  • allergies to any of the test products
  • Presence of an eating disorder
  • Following a restrictive dieting regime
  • Weight loss of >5kg in last 2 months
  • Smoking cigarettes
  • Alcohol intake >2 drinks/day
  • using prescription medications or Natural Health Products;
  • any condition which, in the opinion of the investigator might jeopardize the health and safety of the subject or study personnel, or adversely affect the study results
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment # 1

    Soluble viscous fibre blend powder in hydrophobic matrix

    Dietary Supplement: Soluble viscous fibre blend powder in hydrophobic matrix

  • Experimental
    Treatment # 2

    Soluble viscous fibre blend in pre hydrated form

    Dietary Supplement: Soluble viscous fibre blend in pre hydrated form

  • Placebo comparator
    Control # 1

    No soluble viscous fibre blend

    Dietary Supplement: No soluble viscous fibre blend

  • Experimental
    Treatment # 3

    Soluble viscous fibre blend premixed with ½ carbohydrate gel

    Dietary Supplement: Soluble viscous fibre blend premixed with ½ carbohydrate gel

  • Placebo comparator
    Control # 2

    No soluble viscous fibre blend, ½ carbohydrate jello

    Dietary Supplement: No soluble viscous fibre blend, ½ carbohydrate jello

Interventions

  • Dietary supplementSoluble viscous fibre blend powder in hydrophobic matrix

    5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello

  • Dietary supplementSoluble viscous fibre blend in pre hydrated form

    0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello

  • Dietary supplementNo soluble viscous fibre blend

    0g soluble viscous fibre blend margarine + white bread + jello

  • Dietary supplementSoluble viscous fibre blend premixed with ½ carbohydrate gel

    Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose

  • Dietary supplementNo soluble viscous fibre blend, ½ carbohydrate jello

    Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose

06

What researchers measure

Primary outcomes

  1. Postprandial glycemia

    To investigate the effectiveness of soluble dietary fibre blend supplementation depending on 1) mode of administration and 2) carbohydrate incorporation on reducing postprandial glycemia when consumed with a standardized test breakfast.

    Time frame: 5 hours

Secondary outcomes

  1. Satiety

    To investigate the effectiveness of soluble dietary fibre blend supplementation depending on 1) mode of administration and 2) carbohydrate incorporation on subjective satiety when consumed with a standardized test breakfast. At each visit, participants will record their subjective ratings using a 100mm visual analogue scale and these ratings will be combined into a total subjective appetite score.

    Time frame: 5 hours

  2. Second Meal Glycemia

    To investigate the effectiveness of these different methods of administration of konjac fibre blend on postprandial glycemia of the second standardized meal.

    Time frame: 2 hours

  3. Palatability

    At each visit, participants will record their subjective ratings using a 100mm visual analogue scale and these ratings will be combined into a total subjective palatability score.

    Time frame: 5 hours

07

Study locations

1 site
  • St.Michael's Hospital
    Toronto, Ontario, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01657058
Lead sponsor
Unity Health Toronto
Responsible party
Vladimir Vuksan (Professor, Unity Health Toronto) — Principal investigator
First posted
Aug 3, 2012
Start date
Jul 2012
Primary completion
Dec 2012
Completion
Oct 2014 (estimated)
Last update
Mar 7, 2014

Study contacts

Vladimir Vuksan
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion